Literature DB >> 29020678

Ovarian Cancer: A Heterogeneous Disease.

Myriam Kossaï1, Alexandra Leary, Jean-Yves Scoazec, Catherine Genestie.   

Abstract

Ovarian cancer encompasses a collection of neoplasms with distinct clinicopathological and molecular features and prognosis. Despite there being a variety of ovarian cancer subtypes, these are treated as a single disease. Tremendous efforts have been made to characterize these subtypes and identify tumoral pathways and potential biomarkers for therapeutic strategies. As in other cancer types, tumor heterogeneity appears to be very high across subtypes and within a single tumor, representing a major cause of treatment failure. We describe the morphological and molecular heterogeneity among ovarian cancers and discuss recent advances in our understanding of intratumor heterogeneity.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Heterogeneity; Intratumor heterogeneity; Ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 29020678     DOI: 10.1159/000479006

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  73 in total

1.  Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration.

Authors:  Takeshi Okamoto; Hidekazu Suzuki; Katsuyuki Fukuda
Journal:  Clin J Gastroenterol       Date:  2021-03-19

2.  EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.

Authors:  Bastian Czogalla; Christina Kuhn; Sabine Heublein; Elisa Schmöckel; Doris Mayr; Thomas Kolben; Fabian Trillsch; Alexander Burges; Sven Mahner; Udo Jeschke; Anna Hester
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-04       Impact factor: 4.553

Review 3.  Synthetic Lethality in Ovarian Cancer.

Authors:  Akshaya Chandrasekaran; Kevin M Elias
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

4.  A multicomponent-based microemulsion for boosting ovarian cancer therapy through dual modification with transferrin and SA-R6H4.

Authors:  Haijun Zhao; Mengyuan Chen; Zhujiang Zhao; Linjia Zhu; Shaofei Yuan
Journal:  Drug Deliv Transl Res       Date:  2020-10-02       Impact factor: 4.617

5.  A prognostic risk model for ovarian cancer based on gene expression profiles from gene expression omnibus database.

Authors:  Wei Fan; Xiaoyun Chen; Ruiping Li; Rongfang Zheng; Yunyun Wang; Yuzhen Guo
Journal:  Biochem Genet       Date:  2022-06-27       Impact factor: 1.890

6.  Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer.

Authors:  Min Zhou; Bingshu Li; Jianfeng Liu; Li Hong
Journal:  J Inflamm Res       Date:  2021-12-24

7.  BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression.

Authors:  Jing Xu; Zhe Guo; Shuang Yuan; Heli Li
Journal:  Mol Cell Biochem       Date:  2022-02-19       Impact factor: 3.396

8.  CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway.

Authors:  Yang Cao; Xin Xie; Mingzhu Li; Yuhua Gao
Journal:  Onco Targets Ther       Date:  2021-05-13       Impact factor: 4.147

9.  A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma.

Authors:  Zhixiang Yu; Haiyan He; Yanan Chen; Qiuhe Ji; Min Sun
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

10.  MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer.

Authors:  Jun Xiong; Xiaoju He; Yuanyuan Xu; Wei Zhang; Fen Fu
Journal:  J Ovarian Res       Date:  2021-06-02       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.